Alnylam Pharmaceuticals shares fall after FDA advisers weigh in on heart-disease drug
Alnylam Pharmaceuticals Inc. (ALNY) shares fell more than 8% premarket on Thursday after advisers to the U.S. Food and Drug Administration on Wednesday weighed the risks and benefits of the company's treatment for a serious heart condition known as ATTR-CM. The FDA advisory committee voted 9 to 3 that the benefits of the treatment, Onpattro, outweigh its risks in patients with ATTR-CM, but the committee's comments suggest that the drug's label may be limited, analysts say. BMO Capital Markets analyst Kostas Biliouris wrote in a note Wednesday that Onpattro's label will likely be limited to patients who can't get or tolerate tafamidis, the ATTR-CM treatment sold by Pfizer Inc. (PFE) as Vyndaqel and Vyndamax. The FDA advisers seemed to agree with the agency's position that Onpattro's treatment effect is small, Oppenheimer analysts wrote in a note Thursday, adding, "even in the best-case scenario of an unconditional ATTR-CM indication for Onpattro, we would expect payors to generally restrict access to those who do not adequately respond to tafamidis." Both analysts maintain outperform ratings on Alnylam shares, saying investors are more focused on the prospects for a different Alnylam product, Amvuttra. Alnylam shares are down 10.9% in the year to date, while the S&P 500 has gained 16.4%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-14-23 0815ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks